Atp Announces $40 Million In Series A Funding For Srrna Therapeutics Trailblazer Replicate Bioscience
Atp Announces $40 Million In Series A Funding For Srrna Therapeutics Trailblazer Replicate Bioscience
09/08/21, 10:50 AM
Location
new yorkMoney raised
$40 million
Industry
financial services
Round Type
series a
ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune and inflammatory disorders and other diseases, using self-replicating RNA (srRNA). Replicate will use $40 million in committed Series A funding from ATP to advance multiple novel srRNA programs into clinical development.
Company Info
Location
new york, new york, united states
Additional Info
Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP's strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.